PHG vs SYK vs BSX vs EW vs BAX

For growth investors, Boston Scientific Corporation (BSX) is the stronger pick with 19.

9% revenue growth year-over-year, versus -1. 0% for Koninklijke Philips N. V. (PHG). Koninklijke Philips N. V. (PHG) offers the better valuation at 24. 9x trailing P/E (17. 5x forward), making it the more compelling value choice. Analysts rate Stryker Corporation (SYK) a "Buy" — based on 50 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Koninklijke Philips N.

V. (PHG) is the cheapest at 24. 9x versus Edwards Lifesciences Corporation at 45. 2x. On forward P/E, Baxter International Inc. is actually cheaper at 9. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Stryker Corporation wins at 1. 32x versus Edwards Lifesciences Corporation's 3. 89x — a reasonable growth-adjusted valuation.

Over the past 5 years, Boston Scientific Corporation (BSX) delivered a total return of +31.

2%, compared to -74. 3% for Baxter International Inc. (BAX). Over 10 years, the gap is even starker: SYK returned +187. 1% versus BAX's -42. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Boston Scientific Corporation (BSX) is the lower-risk stock at 0.

34β versus Baxter International Inc. 's 1. 37β — meaning BAX is approximately 299% more volatile than BSX relative to the S&P 500. On balance sheet safety, Edwards Lifesciences Corporation (EW) carries a lower debt/equity ratio of 7% versus 164% for Baxter International Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Boston Scientific Corporation (BSX) is pulling ahead at 19.

9% versus -1. 0% for Koninklijke Philips N. V. (PHG). On earnings-per-share growth, the picture is similar: Koninklijke Philips N. V. grew EPS 224. 0% year-over-year, compared to -73. 7% for Edwards Lifesciences Corporation. Over a 3-year CAGR, BSX leads at 16. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Edwards Lifesciences Corporation (EW) is the more profitable company, earning 17.

7% net margin versus -8. 5% for Baxter International Inc. — meaning it keeps 17. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EW leads at 27. 0% versus -2. 7% for BAX. At the gross margin level — before operating expenses — EW leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Stryker Corporation (SYK) is the more undervalued stock at a PEG of 1. 32x versus Edwards Lifesciences Corporation's 3. 89x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Baxter International Inc. (BAX) trades at 9. 2x forward P/E versus 27. 5x for Edwards Lifesciences Corporation — 18. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BSX: 61. 4% to $91. 33.

In this comparison, BAX (3.

9% yield), PHG (1. 5% yield), SYK (1. 1% yield) pay a dividend. BSX, EW do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

55), 1. 1% yield, +187. 1% 10Y return). Both have compounded well over 10 years (SYK: +187. 1%, BAX: -42. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PHG is a mid-cap quality compounder stock; SYK is a mid-cap quality compounder stock; BSX is a mid-cap high-growth stock; EW is a mid-cap quality compounder stock; BAX is a small-cap income-oriented stock. PHG, SYK, BAX pay a dividend while BSX, EW do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.